Watch the live launch of the Antimicrobial Resistance Benchmark – on Tues 23 Jan

On the panel – Jeremy Farrar of Wellcome Trust & Paul Stoffels of Johnson & Johnson

Starting at 14:00 CET on Tuesday 23 January, Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, will present the results of the first Antimicrobial Resistance Benchmark in a live-streamed WEF press conference.

Antibiotics are losing their effectiveness, as people continue to use them too freely. To slow the rise of antimicrobial resistance (AMR), antimicrobials must be used only when necessary. Pharmaceutical companies can help bring AMR under control, by developing new antimicrobials and by producing and selling antimicrobials responsibly.

The Benchmark compares pharmaceutical company action to tackle antimicrobial resistance (AMR). It compares 30 companies, a cross-section of the pharmaceutical industry, on their actions to bring AMR under control. These include those companies with the largest R&D divisions, the largest presence in antimicrobial markets, and specific expertise in developing critically needed medicines and vaccines.

The Benchmark will first be presented in a press conference at the Annual Meeting of the World Economic Forum in Davos, Switzerland. At the same time, the full Benchmark report will be made available to download from

Watch the launch live
The press conference will start at 14:00 CET and can be watched live via the WEF website. During the press conference, Jayasree Iyer will present the Benchmark and its key findings for the first time.

The press conference panel
• Jayasree K. Iyer, Executive Director, Access to Medicine Foundation
• Paul Stoffels, Executive Vice President and Chief Medical Officer, Johnson & Johnson
• Jeremy Farrar, Director, Wellcome Trust

The panel discussion will be moderated by Georg Schmidt, Associate Director, Public Engagement, Media Relations, World Economic Forum

Date: Tuesday, 23 January, 2018
Time: 14:00 – 14:30 (CET)
Location: Media Village, Press Conference Room

During the WEF Annual Meeting, Jayasree will speak about AMR and the Benchmark in two further sessions: in a private session and in a panel discussion entitled ‘A New Era for Global Health’ alongside Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation and Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO).

More about the upcoming report
The full Benchmark report includes findings in all of the metrics used by the Benchmark. It includes a comparative assessment of companies’ performances, as well as Key Findings, portfolio and pipeline analyses and investigations of company action in three research areas: Research & Development, Manufacturing & Production and Appropriate Access & Stewardship. Each of the 30 companies evaluated has a detailed report card to give an overview of its performance.

The Benchmark will be available to download from It is funded by the UK Department for International Development and the Dutch Ministry for Health, Welfare and Sport.

About the Access to Medicine Index

The Access to Medicine Index analyses 20 of the world’s largest research-based pharmaceutical companies with products for high-burden diseases in low- and middle-income countries. The Index ranks these companies according to their efforts to improve access to medicine in seven areas of corporate behaviour, including pricing, patents, ethical behaviour and donations. It covers 107 low- and middle-income countries and 50 high-burden diseases, and examines eight types of products, from medicines to vaccines to diagnostics. The Index identifies best practices, highlights where progress is being made, and uncovers where critical action is still required. In this way, the Index provides both an incentive and a guide for pharmaceutical companies to do more to improve access to medicine. It is published every two years by the Access to Medicine Foundation, an independent non-profit organisation.

About the Access to Medicine Foundation

The Access to Medicine Foundation is a non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine. The Foundation is funded by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs and the UK Department for International Development. For ten years, the Foundation has been building consensus on the role for the pharmaceutical industry in improving access to medicine and vaccines. It published its first benchmark of industry activity in this area in 2008, in the first Access to Medicine Index. The fifth Access to Medicine Index has been published in 2016.